Quality doesn’t always match quantity of survival with pembrolizumab
By Mardi Chapman
11 Feb 2020
Health-related quality of life (HRQOL) in patients with metastatic non-squamous non-small-cell lung cancer without sensitising EGFR mutations or ALK translocations is maintained or marginally improved with the addition of pembrolizumab to standard chemotherapy. Patient reported outcomes in the international KEYNOTE-189 study of more than 600 patients, found HRQOL was maintained from baseline to week 21 ...